Pfizer and Sanofi helped the precision medicine developer close a series B round which will be used to advance and expand its pipeline of respiratory disease drug candidates.
Recode Therapeutics, a US-based biopharmaceutical spinout of University of Texas (UT) Southwestern Medical Center, completed an $80m series B round co-led by pharmaceutical company Pfizer on Wednesday.
The round was co-led with investment adviser EcoR1 Capital and included pharmaceutical firm Sanofi as well as Tekla Capital Management, Superstring Capital, NS Investment, OrbiMed, Vida Ventures, MPM Capital, Colt Ventures, Hunt Technology Ventures and Osage University Partners (OUP).
Pfizer and Sanofi invested in the round through their respective corporate venturing arms: Pfizer…
